GLP‑1 treatment in Delaware
Who ships GLP-1 medication to Delaware, what Medicaid covers, and the telehealth rules that apply.
What the federal data shows for Delaware
936 clinicians in Delaware prescribed Ozempic to Medicare Part D patients in 2024, across 33,326 claims. That is the most-prescribed GLP-1 in the state by prescriber count. Part D covers Medicare only, so the figure is a floor on prescribing in Delaware rather than a total.
Delaware Medicaid reimbursed $5,025,737.10 for 10,844 GLP-1 prescriptions in Q1 2026, or $463.46 per prescription. From CMS State Drug Utilization, fee-for-service and managed care combined. Suppressed cells are excluded, never counted as zero.
No outsourcing facility registered under section 503B gives a Delaware address in the FDA register. A compounded prescription filled for a Delaware patient is dispensed from a facility registered elsewhere.
What is on this page
- 6 drug cost pages for Delaware, each pairing the state's Medicaid figures with pharmacy acquisition cost
- 2 city pages showing where GLP-1 prescribers practise in Delaware
- Every link below is a page for Delaware specifically, not a national page filtered to it
- CMS NADACNational Average Drug Acquisition Cost, weekly file
- CMS Medicare Part DPrescriber public use file, by geography and drug
- CMS State Drug UtilizationQuarterly Medicaid prescription and reimbursement data
NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.